| 敬琳,杨昆,姚静,等.精神分裂症断裂基因 1基因多态性与帕利哌酮治疗精神分裂症疗效及微小 RNA?134?5p关联性分析[J].安徽医药,2020,24(8):1553-1557. |
| 精神分裂症断裂基因 1基因多态性与帕利哌酮治疗精神分裂症疗效及微小 RNA?134?5p关联性分析 |
| Analysis of efficacy and association between DISC1 gene polymorphism and palipiazone in the treatment of schizophrenia |
| |
| DOI：10.3969/j.issn.1009?6469.2020.08.018 |
| 中文关键词: 精神分裂症 多态性，单核苷酸 精神分裂症断裂基因 1 微小 RNA?134?5p 帕利哌酮 |
| 英文关键词: Schizophrenia Polymorphism,single nucleotide Schizophrenia break gene 1 MicroRNA?134?5p Paliperidone |
| 基金项目:四川省卫计委科研课题(18PJ315) |
|
| 摘要点击次数: 2084 |
| 全文下载次数: 596 |
| 中文摘要: |
| 目的观察精神分裂症断裂基因 1(dierupted in schizophrenia 1，DISC1)基因多态性与帕利哌酮治疗精神分裂症疗效及微小 RNA?134?5p(miR?134?5p)的关联性分析。方法选取 2018年 3月至 2019年 3月绵阳市第三人民医院精神分裂症病人 109例为疾病组，采用帕利哌酮单药治疗，选取同期健康体检者 109例为健康组，检测并比较两组 DISC1基因单核苷酸多态性(SNPs)位点间差异。比较疾病组不同基因型病人帕利哌酮治疗前与治疗 6个月后阳性和阴性症状量表(PANSS)、精神分裂症认知功能成套测验共识版(MCCB)评分以及血清 miR?134?5p水平。结果 DISC1 SNPs位点比较中，疾病组 rs821616位点与健康组差异有统计学意义(P＜0.05)。疾病组不同基因型病人帕利哌酮治疗后 PANSS评分均较治疗前降低， MCCB评分较治疗前升高(P＜0.05)。 rs821616基因型病人中 TT型病人 PANSS评分(46.3±7.1)分低于 AA型病人(59.4±5.8)分， TT型病人 MCCB评分(154.7±32.3)分高于 AA型病人(131.3±32.1)分， AT型(0.32±0.07)和 TT型(0.41±0.09)病人 miR?134?5p水平高于 AA型病人(0.30±0.11)。 rs11122319基因型病人中 GG型、 AG型病人 PANSS评分低于 AA型病人， GG型病人 MCCB评分和 miR?134?5p水平高于 AA型和 AG型病人(P＜0.05)。 rs1417584基因型病人中 GG型、 AG型病人 PANSS评分低于 AA型病人， GG型病人 MCCB评分高于 AA型和 AG型， GG型病人 miR?134?5p水平高于 AA型病人(P＜0.05)。结论帕利哌酮可以改善精神分裂症病人症状，改善病人认知功能，提高 miR?134?5p水平，不同 DISC1基因型病人间治疗效果存在差异。 |
| 英文摘要: |
| Objective To investigate the association between polymorphism of schizophrenia 1(DISC1)gene and the therapeutic effect of paliperidone on patients with schizophrenia and miR?134?5p.Methods One hundred and nine patients with schizophrenia in the Third People’s Hospital of Mianyang City from March 2018 to March 2019 were selected as the disease group and treatedwith paliperidone monotherapy.109 healthy subjects in the same period were enrolled in the study as control group.The different ofsingle nucleotide polymorphism(SNPs)sites of DISC1 gene between the two groups were detected and compared.Positive and nega? tive symptoms scale(PANSS)，schizophrenia cognitive function test consensus test(MCCB)score，and serum miR?134?5p level ofpatients with different genotypes of schizophrenia in disease group before and after 6 months of paliperidone treatment were com?pared.Results In the comparison of SNPs of DISC1，the difference of rs821616 locus between the disease group and the healthy group was statistically significant(P＜0.05).The PANSS scores of patients with different genotypes in patients with schizophrenia decreased after treatment，and the MCCB scores were higher than those before treatment(P＜0.05).Among the patients with rs821616 genotype，the PANSS score of patients with TT(46.3±7.1)was lower than that of AA(59.4±5.8)patients，and the MC? CB score was higher than that of AA patients［(154.7±32.3)vs.(131.3±32.1)］ .The level of miR?134?5p in patients with AT(0.32±0.07)and TT(0.41±0.09)was higher than that of AA patients(0.30±0.11).In patients with rs11122319 genotype，the PANSS scores of patients with GG and AG were lower than those of AA patients，the MCCB scores and miR?134?5p levels of pa? tients with GG were higher than those of AA and AG(all P＜0.05).In patients with rs1417584 genotype，the PANSS scores of pa? tients with GG and AG were lower than those of AA patients，the MCCB scores of patients with GG were higher than those of AA and AG，the level of miR?134?5p in patients with GG was higher than that of AA patients(all P＜0.05).Conclusion Pariprazonecan improve psychotic symptoms in patients with schizophrenia，improve the cognitive function of patients，and increase the level of miR?134?5p.The therapeutic effects of different DISC1 genotypes are different. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
